These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9219043)

  • 21. Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review.
    Whale R; Terao T; Cowen P; Freemantle N; Geddes J
    J Psychopharmacol; 2010 Apr; 24(4):513-20. PubMed ID: 18832428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.
    Roose SP; Laghrissi-Thode F; Kennedy JS; Nelson JC; Bigger JT; Pollock BG; Gaffney A; Narayan M; Finkel MS; McCafferty J; Gergel I
    JAMA; 1998 Jan; 279(4):287-91. PubMed ID: 9450712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression.
    Golden RN; Nemeroff CB; McSorley P; Pitts CD; Dubé EM
    J Clin Psychiatry; 2002 Jul; 63(7):577-84. PubMed ID: 12143913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
    Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH
    J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.
    Richard IH; McDermott MP; Kurlan R; Lyness JM; Como PG; Pearson N; Factor SA; Juncos J; Serrano Ramos C; Brodsky M; Manning C; Marsh L; Shulman L; Fernandez HH; Black KJ; Panisset M; Christine CW; Jiang W; Singer C; Horn S; Pfeiffer R; Rottenberg D; Slevin J; Elmer L; Press D; Hyson HC; McDonald W;
    Neurology; 2012 Apr; 78(16):1229-36. PubMed ID: 22496199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment.
    Pérez V; Gilaberte I; Faries D; Alvarez E; Artigas F
    Lancet; 1997 May; 349(9065):1594-7. PubMed ID: 9174562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression.
    Maes M; Vandoolaeghe E; Desnyder R
    J Affect Disord; 1996 Dec; 41(3):201-10. PubMed ID: 8988452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
    Weihs KL; Settle EC; Batey SR; Houser TL; Donahue RM; Ascher JA
    J Clin Psychiatry; 2000 Mar; 61(3):196-202. PubMed ID: 10817105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.
    Preskorn SH; Baker B; Kolluri S; Menniti FS; Krams M; Landen JW
    J Clin Psychopharmacol; 2008 Dec; 28(6):631-7. PubMed ID: 19011431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of controlled-release paroxetine in the treatment of late-life depression.
    Rapaport MH; Schneider LS; Dunner DL; Davies JT; Pitts CD
    J Clin Psychiatry; 2003 Sep; 64(9):1065-74. PubMed ID: 14628982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of pindolol and milnacipran versus milnacipran and placebo on plasma prolactin and adrenocorticotrophic hormone in depressed subjects.
    Isaac MB; Isaac MT
    Hum Psychopharmacol; 2003 Oct; 18(7):569-74. PubMed ID: 14533141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial.
    Braconnier A; Le Coent R; Cohen D;
    J Am Acad Child Adolesc Psychiatry; 2003 Jan; 42(1):22-9. PubMed ID: 12500073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost effectiveness study of a year follow-up of selective serotonin reuptake inhibitor (SSRI) and augmentor combination compared with SSRI and placebo.
    Tome MB; Isaac MT
    Int Clin Psychopharmacol; 1998 Jul; 13(4):175-82. PubMed ID: 9727728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
    Burke WJ; Gergel I; Bose A
    J Clin Psychiatry; 2002 Apr; 63(4):331-6. PubMed ID: 12000207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
    Bielski RJ; Ventura D; Chang CC
    J Clin Psychiatry; 2004 Sep; 65(9):1190-6. PubMed ID: 15367045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder.
    Kasper S; Olivieri L; Di Loreto G; Dionisio P
    Curr Med Res Opin; 2005 Aug; 21(8):1139-46. PubMed ID: 16083521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.